New Drug and Blood Test Could Transform Preventive Medicine

A New Era in Early Detection and Treatment

Two medical breakthroughs are converging to reshape preventive healthcare: a first-in-class drug that tames dangerously high blood pressure when nothing else works, and a single blood draw that can screen for more than 50 types of cancer before symptoms ever appear. Together, they signal a shift toward catching and controlling the world's deadliest conditions far earlier than current medicine allows.

Baxdrostat: Hope for Resistant Hypertension

For the estimated 10–20% of hypertension patients whose blood pressure remains stubbornly elevated despite three or more medications, treatment options have long been limited. Baxdrostat, a selective aldosterone synthase inhibitor developed by AstraZeneca, targets the root cause by blocking production of aldosterone — a hormone increasingly implicated in treatment-resistant cases.

Results from the BaxHTN Phase 3 trial, published in the New England Journal of Medicine and presented at the 2025 European Society of Cardiology Congress, are striking. Among 794 patients randomized across 12 weeks, the 2 mg dose of baxdrostat reduced systolic blood pressure by 15.7 mmHg from baseline — nearly 10 mmHg more than placebo. Roughly 40% of patients achieved blood pressure below 130 mmHg, compared with just 18.7% on placebo.

Safety data were reassuring. Serious adverse events occurred at rates comparable to placebo, and no cases of adrenocortical insufficiency were reported. Elevated potassium — a known risk with aldosterone-targeting drugs — led to discontinuation in fewer than 2% of participants. "This represents a novel pharmacological strategy for patients who have essentially run out of options," the European Society of Cardiology noted in its press release.

Galleri: One Blood Test, 50+ Cancers

Meanwhile, the Galleri test by GRAIL is pushing cancer screening into new territory. The liquid biopsy analyzes cell-free DNA fragments shed by tumors into the bloodstream, using methylation patterns to detect a cancer signal and identify its likely tissue of origin — all from a standard blood draw.

The Pathfinder 2 trial, involving nearly 36,000 participants aged 50 and older, showed the test detected cancer in 133 individuals who had no clinical suspicion of the disease. The positive predictive value reached 61.6%, meaning that for roughly every ten positive results, six were confirmed cancers. Over half of those cancers were caught at stage I or II, when treatment is most effective. When added to standard screenings for breast, cervical, colorectal, and lung cancer, Galleri increased overall cancer detection seven-fold.

As Harvard Health notes, such tests are especially promising for the many cancer types — pancreatic, ovarian, liver — that currently lack any routine screening method. However, the test is not yet FDA-approved, costs between $700 and $950 out of pocket, and a positive result still requires follow-up imaging and biopsy for confirmation.

The Bigger Picture

Hypertension kills an estimated 10 million people annually worldwide, while cancer claims nearly another 10 million. Both conditions share a critical vulnerability: outcomes improve dramatically with earlier intervention. Baxdrostat addresses a population that existing drugs simply cannot reach, while Galleri aims to catch cancers years before they become lethal.

A large-scale NHS trial in the United Kingdom involving over 140,000 participants is expected to deliver results on Galleri's real-world impact in 2026. AstraZeneca, meanwhile, is advancing additional baxdrostat trials across Asia and in extended-duration studies. If both deliver on their early promise, preventive medicine could look fundamentally different within the decade.